Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.41 |
| ▸ | EPOR | P19235 | 3/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21572001 | 0.93 | GLP1R (0.59) | GLP1RFOLH1 | |
| SCHEMBL20936257 | 0.91 | GLP1R (0.50) | GLP1RFOLH1EPOREPHX2 | |
| SCHEMBL20936259 | 0.91 | GLP1R (0.50) | GLP1RFOLH1EPOREPHX2 | |
| SCHEMBL23544197 | 0.89 | GLP1R (0.50) | GLP1RFOLH1EPOREPHX2 | |
| SCHEMBL19057815 | 0.86 | GLP1R (0.66) | GLP1RFOLH1EPHX2 | |
| SCHEMBL23552462 | 0.86 | GLP1R (0.66) | GLP1RFOLH1EPHX2 | |
| SCHEMBL22423517 | 0.86 | GLP1R (0.49) | GLP1RFOLH1EPOREPHX2 | |
| SCHEMBL23552373 | 0.84 | GLP1R (0.51) | GLP1RFOLH1 | |
| SCHEMBL19057814 | 0.84 | GLP1R (0.51) | GLP1R | |
| SCHEMBL20936258 | 0.84 | GLP1R (0.62) | GLP1RFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10479819-B2 | Oxyntomodulin analogue | JIANG, Xianxing (CN) | 2019-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479819-B2 | Oxyntomodulin analogue | GCGR, GLP1R, GIPR | GLP1R 2/4885FOLH1 536/4885EPOR 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.